Osteoarthritis - Pipeline Review, H2 2017

Date: August 22, 2017
Pages: 240
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O6DE0DB7DF6EN
Leaflet:

Download PDF Leaflet

Osteoarthritis - Pipeline Review, H2 2017
Osteoarthritis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H2 2017, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape.

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 8, 16, 9, 44 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 5 molecules, respectively.

Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Osteoarthritis - Overview
Osteoarthritis - Therapeutics Development
Osteoarthritis - Therapeutics Assessment
Osteoarthritis - Companies Involved in Therapeutics Development
Osteoarthritis - Drug Profiles
Osteoarthritis - Dormant Projects
Osteoarthritis - Discontinued Products
Osteoarthritis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Osteoarthritis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Osteoarthritis - Pipeline by 4P-Pharma SAS, H2 2017
Osteoarthritis - Pipeline by AbbVie Inc, H2 2017
Osteoarthritis - Pipeline by Abiogen Pharma SpA, H2 2017
Osteoarthritis - Pipeline by Ablynx NV, H2 2017
Osteoarthritis - Pipeline by Amgen Inc, H2 2017
Osteoarthritis - Pipeline by Amura Holdings Ltd, H2 2017
Osteoarthritis - Pipeline by Anterogen Co Ltd, H2 2017
Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp, H2 2017
Osteoarthritis - Pipeline by Axsome Therapeutics Inc, H2 2017
Osteoarthritis - Pipeline by Biopharm GmbH, H2 2017
Osteoarthritis - Pipeline by Bone Therapeutics SA, H2 2017
Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd, H2 2017
Osteoarthritis - Pipeline by Cardax Inc, H2 2017
Osteoarthritis - Pipeline by Cellular Biomedicine Group Inc, H2 2017
Osteoarthritis - Pipeline by Corestem Inc, H2 2017
Osteoarthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Osteoarthritis - Pipeline by Eli Lilly and Company, H2 2017
Osteoarthritis - Pipeline by Evgen Pharma Plc, H2 2017
Osteoarthritis - Pipeline by Galapagos NV, H2 2017
Osteoarthritis - Pipeline by Gemphire Therapeutics Inc, H2 2017
Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H2 2017
Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H2 2017
Osteoarthritis - Pipeline by InKemia IUCT Group SA, H2 2017
Osteoarthritis - Pipeline by International Stem Cell Corp, H2 2017
Osteoarthritis - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
Osteoarthritis - Pipeline by K-Stemcell Co Ltd, H2 2017
Osteoarthritis - Pipeline by Kang Stem Biotech Co Ltd, H2 2017
Osteoarthritis - Pipeline by Lateral Pharma Pty Ltd, H2 2017
Osteoarthritis - Pipeline by Levolta Pharmaceuticals Inc, H2 2017
Osteoarthritis - Pipeline by LG Chem, Ltd., H2 2017
Osteoarthritis - Pipeline by Marina Biotech Inc, H2 2017
Osteoarthritis - Pipeline by Medivir AB, H2 2017
Osteoarthritis - Pipeline by Merck KGaA, H2 2017
Osteoarthritis - Pipeline by Mesoblast Ltd, H2 2017
Osteoarthritis - Pipeline by Mor Research Application Ltd, H2 2017
Osteoarthritis - Pipeline by Nordic Bioscience A/S, H2 2017
Osteoarthritis - Pipeline by Novartis AG, H2 2017
Osteoarthritis - Pipeline by NovelMed Therapeutics Inc, H2 2017
Osteoarthritis - Pipeline by Osteologix Holdings Plc, H2 2017
Osteoarthritis - Pipeline by Pfizer Inc, H2 2017
Osteoarthritis - Pipeline by Pharmalink AB, H2 2017
Osteoarthritis - Pipeline by Philogen SpA, H2 2017
Osteoarthritis - Pipeline by PhytoHealth Corp, H2 2017
Osteoarthritis - Pipeline by PLx Pharma Inc, H2 2017
Osteoarthritis - Pipeline by ProteoThera Inc, H2 2017
Osteoarthritis - Pipeline by Regeneus Ltd, H2 2017
Osteoarthritis - Pipeline by Regulaxis SAS, H2 2017
Osteoarthritis - Pipeline by Rottapharm Biotech Srl, H2 2017
Osteoarthritis - Pipeline by Samumed LLC, H2 2017
Osteoarthritis - Pipeline by Seikagaku Corp, H2 2017
Osteoarthritis - Pipeline by Stelis Biopharma Pvt Ltd, H2 2017
Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Osteoarthritis - Pipeline by TissueGene Inc, H2 2017
Osteoarthritis - Pipeline by Traverse Biosciences Inc, H2 2017
Osteoarthritis - Pipeline by Unity Biotechnology Inc, H2 2017
Osteoarthritis - Pipeline by Yooyoung Pharm Co Ltd, H2 2017
Osteoarthritis - Pipeline by Yuhan Corp, H2 2017
Osteoarthritis - Pipeline by Yungjin Pharm Co Ltd, H2 2017
Osteoarthritis - Pipeline by Zimmer Biomet Holdings Inc, H2 2017
Osteoarthritis - Dormant Projects, H2 2017
Osteoarthritis - Dormant Projects, H2 2017 (Contd..1), H2 2017
Osteoarthritis - Dormant Projects, H2 2017 (Contd..2), H2 2017
Osteoarthritis - Dormant Projects, H2 2017 (Contd..3), H2 2017
Osteoarthritis - Dormant Projects, H2 2017 (Contd..4), H2 2017
Osteoarthritis - Dormant Projects, H2 2017 (Contd..5), H2 2017
Osteoarthritis - Discontinued Products, H2 2017
Osteoarthritis - Discontinued Products, H2 2017 (Contd..1), H2 2017

LIST OF FIGURES

Number of Products under Development for Osteoarthritis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

4P-Pharma SAS
AbbVie Inc
Abiogen Pharma SpA
Ablynx NV
Amgen Inc
Amura Holdings Ltd
Anterogen Co Ltd
Asahi Kasei Pharma Corp
Axsome Therapeutics Inc
Biopharm GmbH
Bone Therapeutics SA
Can-Fite BioPharma Ltd
Cardax Inc
Cellular Biomedicine Group Inc
Corestem Inc
Dong-A Socio Holdings Co Ltd
Eli Lilly and Company
Evgen Pharma Plc
Galapagos NV
Gemphire Therapeutics Inc
Genequine Biotherapeutics GmbH
GlaxoSmithKline Plc
InKemia IUCT Group SA
International Stem Cell Corp
Jeil Pharmaceutical Co Ltd
K-Stemcell Co Ltd
Kang Stem Biotech Co Ltd
Lateral Pharma Pty Ltd
Levolta Pharmaceuticals Inc
LG Chem, Ltd.
Marina Biotech Inc
Medivir AB
Merck KGaA
Mesoblast Ltd
Mor Research Application Ltd
Nordic Bioscience A/S
Novartis AG
NovelMed Therapeutics Inc
Osteologix Holdings Plc
Pfizer Inc
Pharmalink AB
Philogen SpA
PhytoHealth Corp
PLx Pharma Inc
ProteoThera Inc
Regeneus Ltd
Regulaxis SAS
Rottapharm Biotech Srl
Samumed LLC
Seikagaku Corp
Stelis Biopharma Pvt Ltd
Takeda Pharmaceutical Company Ltd
TissueGene Inc
Traverse Biosciences Inc
Unity Biotechnology Inc
Yooyoung Pharm Co Ltd
Yuhan Corp
Yungjin Pharm Co Ltd
Zimmer Biomet Holdings Inc
Skip to top


Bone Medical Limited - Product Pipeline Review - 2015 US$ 1,500.00 Oct, 2015 · 28 pages

Ask Your Question

Osteoarthritis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: